Clonal heterogeneity as a driver of disease variability in the evolution of myeloproliferative neoplasms. [PDF]
, 2014 Myeloproliferative neoplasms (MPNs) are clonal hematological diseases in which cells of the myelo-erythroid lineage are overproduced and patients are predisposed to leukemic transformation.
de Haan, Gerald +3 more
core +1 more source
Ubiquitylation in immune disorders and cancer: from molecular mechanisms to therapeutic implications [PDF]
, 2012 Conjugation of ubiquitin to proteins (ubiquitylation) has emerged to be one of the most crucial post-translational modifications controlling virtually all cellular processes.
Fulda, Simone +2 more
core +2 more sources
Brain MRI-findings in Ph - negative myeloproliferative disorders
Терапевтический архив, 2019 Myeloproliferative disorders (MPD) are accompanied by a high proportion of thrombotic complications, which may lead to cerebrovascular disease (CVD). Aim.
M M Tanashyan +5 more
doaj +1 more source
PLoS ONE, 2020 The myeloproliferative neoplasms, polycythemia vera, essential thrombocytosis and primary myelofibrosis are hematopoietic stem cell disorders and share driver mutations that either directly activate the thrombopoietin receptor, MPL, or activate it ...
Jerry L Spivak +8 more
doaj +1 more source
Mutant Cbl proteins as oncogenic drivers in myeloproliferative disorders
OncoTarget, 2011 Casitas B-lineage lymphoma (Cbl) family proteins are evolutionarily-conserved attenuators of protein tyrosine kinase (PTK) signaling. Biochemical analyses over the past two decades have firmly established that the negative regulatory functions of Cbl ...
M. Naramura +9 more
semanticscholar +1 more source
Platelets as mediators of Thromboinflammation in chronic Myeloproliferative Neoplasms [PDF]
, 2019 Chronic myeloproliferative neoplasms (MPN) are stem cell disorders driven by mutations in JAK2, CALR, or MPL genes and characterized by myeloid proliferation and increased blood cell counts.
Heller, Paula Graciela +1 more
core +1 more source
Differential NOD/SCID mouse engraftment of peripheral blood CD34 + cells and JAK2V617F clones from patients with myeloproliferative neoplasms [PDF]
, 2010 We evaluated the NOD/SCID engraftment of CD34 + cells from polycythemia vera (PV) and secondary polycythemia patients (SP) and the JAK2V617F clone before and after transplantation. Peripheral blood CD34 + cells were transplanted intra-femorally.
Cheung, AMS +4 more
core +1 more source
Severe Case of Peripheral Leukocytosis Initially Diagnosed as Myelodysplastic Syndrome/Myeloproliferative Neoplasm, Unclassifiable, but Possibly Prefibrotic Primary Myelofibrosis [PDF]
, 2014 Leukocytosis is occasionally seen in patients with presumptive but undiagnosed myeloproliferative disorders (MPD). A 74-year-old woman was admitted to our hospital for tarry stools, anemia, and marked peripheral leukocytosis of 1.4×105/μL ...
Hiramatsu, Yasushi +8 more
core +1 more source
Frequency of heterozygous TET2 deletions in myeloproliferative neoplasms
Cancer Management and Research, 2010 Joseph Tripodi1, Ronald Hoffman1, Vesna Najfeld2, Rona Weinberg31The Myeloproliferative Disorders Program, Tisch Cancer Institute, Department of Medicine and 2Department of Medicine and Pathology, Mount Sinai School of Medicine, 3The Myeloproliferative ...
Joseph Tripodi +3 more
doaj
Reactivation of Pulmonary Tuberculosis following Treatment of Myelofibrosis with Ruxolitinib
Case Reports in Hematology, 2016 Ruxolitinib is widely in use for treatment of myeloproliferative disorders. It causes inhibition of the Janus kinase (JAK) signal transducer and activation of transcription (STAT) pathway, which plays a key role in the underlying pathophysiology of ...
Maheen Z. Abidi +6 more
doaj +1 more source